ACHL

Companies
NASDAQ
Achilles Therapeutics plc - ADR
Health Care
Price Chart
Overview

About ACHL

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Market Cap
$38.5M
Volume
1.2M
Avg. Volume
1.9M
P/E Ratio
-0.7914439
Dividend Yield
0.00%
Employees
226.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.53
Low Correlation
Volatility
High (0.59)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ACHL.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ACHL shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$38.5M
Volume1.2M
P/E Ratio-0.79
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
August 14, 2024
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how ACHL fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025